WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced significant changes to its leadership team, naming Lindsay Androski, J.D., M.B.A., as Chief Executive Officer. Ms. Androski succeeds Michael J. McElhaugh, who had been serving as the company’s Interim President and CEO. She will also join the company’s newly restructured board of directors.
Ms. Androski, an MIT-trained biologist with nearly three decades of experience spanning biotechnology, law, and academia, brings extensive expertise to her new role. Her background includes various leadership roles at Roivant and serving as special counsel at Genevant, where her focus has included litigation related to lipid nanoparticle (LNP) technology.
Commenting on her appointment, Androski said, “I would like to thank Michael McElhaugh and the rest of the board for their service. Along with Arbutus’s new directors, I am excited to lead the company into its next chapter. We believe these changes in leadership will enable renewed focus on advancing the company’s pipeline efficiently and maximizing the company’s contributions to LNP delivery technology through Genevant, both of which we expect will deliver greater value to shareholders and patients alike.”
The leadership restructuring also includes the addition of four new directors to its board—Robert Alan Beardsley, Joseph Bishop, Matthew Gline, and Anuj Hasija. With this transition, the existing board members have stepped down, reducing the board size to five members. The company has indicated plans to potentially expand the board by adding individuals with expertise in clinical development.
To facilitate the transition and allow the new leadership team to review strategic priorities, Arbutus has announced a temporary pause in participating in investor meetings and conferences. Areas under review include the company’s development plans for hepatitis B programs and its broader strategic framework.
These sweeping changes mark a pivotal moment for Arbutus Biopharma. Under Ms. Androski’s leadership and the renewed focus of the board, the company is positioned to accelerate progress in its pipeline and expand its contributions to cutting-edge LNP delivery technology. This new direction could redefine the company’s impact on both the biotechnology sector and patient outcomes moving forward.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.